SNS-314

• CAT Number: I000543
• CAS Number: 1146618-41-8
• Molecular Weight: 527
• Purity: ≥95%
• Target: Aurora Kinase
• Solubility: DMSO ≥102 mg/mL Water ≥5.7 mg/mL Ethanol <1.2 mg/mL
• Storage: 3 years -20C powder
• IC50: 9.0 nM(Aurora A); 31 nM(Aurora B); 3 nM(Aurora C)
• InChIKey: FYCODPVDEFFWSR-UHFFFAOYSA-N

SNS-314 (CAT: I000543) is a potent and selective inhibitor of Aurora kinase A and B, which are important regulators of cell division and mitosis. By inhibiting these kinases, SNS-314 disrupts the proper formation and function of the mitotic spindle, leading to cell cycle arrest and inhibition of tumor cell proliferation. SNS-314 has demonstrated broad antitumor activity in preclinical studies, including inhibition of tumor growth in xenograft models of various cancer types. It has also shown efficacy against drug-resistant tumor cells and synergistic effects when used in combination with other anticancer agents. SNS-314 holds promise as a targeted therapy for the treatment of cancer and is currently being investigated in clinical trials.

Reference

[1]. VanderPorten EC et al. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model Mol Cancer Ther. 2009 Apr;8(4):930-9 


[2]. Arbitrario JP et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar; 65(4):707-17 


[3]. Zhang B, Li Y, Zhang H, Ai C.3D-QSAR and Molecular Docking Studies on Derivatives of MK-0457, GSK1070916 and SNS-314 as Inhibitors against Aurora B Kinase.Int J Mol Sci. 2010 Nov 2;11(11):4326-47. 


[4]. Zhong M, Bui M, Shen W, Baskaran S, Allen DA, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris SO, Heumann SA, Hoch U, Ivy SN, Jacobs JW, Lam S, Lee H, McDowell RS, Oslob JD, Purkey HE, Romanowski MJ, Silverman JA, Tangonan BT, Taverna P, Yang W, Yoburn JC, Yu CH, Zimmerman KM, O/’Brien T, Lew W.2-Aminobenzimidazoles as potent Aurora kinase inhibitors.Bioorg Med Chem Lett. 2009 Sep 1;19(17):5158-61. Epub 2009 Jul 9. 


[5]. Tomillero A, Moral MA.Gateways to clinical trials.Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57.